NewAmsterdam Pharma Ratios (2022-2025) | NAMS

Ratios Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Profitability
EBT Margin -486.94%-2,230.11%-1,602.62%-6,160.40%-6,692.86%-1,711.58%-57.19%-721.71%-1,327.30%-90.70%-20,691.09%
EBIT Margin -461.85%-2,474.20%-1,685.07%-6,360.40%-3,960.17%-2,306.93%-85.89%-338.47%-2,314.47%-186.13%-15,845.69%
EBITDA Margin -486.94%-2,230.11%-1,602.62%-6,163.76%-6,692.86%-1,711.58%-57.18%-721.36%-1,328.41%-91.26%-20,601.15%
Operating Margin -461.85%-2,474.20%-1,685.07%-6,360.40%-3,960.17%-2,306.93%-85.89%-338.47%-2,314.47%-186.13%-15,845.69%
Net Margin -486.94%-1,602.62%-6,160.40%-6,692.86%-1,711.58%-57.18%-721.71%-1,327.30%-90.70%-20,691.09%
FCF Margin -369.34%-1,597.59%-4,119.18%-3,924.84%-2,377.71%-43.20%-293.49%-1,225.12%-197.23%-9,428.45%
Efficiency
Assets Average 417.78M467.58M442.94M651.91M841.52M816.76M800.77M
Equity Average 446.37M385.88M352.59M310.11M350.10M399.62M383.15M568.18M767.43M777.93M753.28M
Invested Capital 498.30M398.41M0.01M331.83M300.97M444.86M410.98M397.76M795.01M800.89M799.43M772.43M
Asset Utilization Ratio 0.020.020.080.070.060.080.04
Leverage & Solvency
Debt to Equity 0.010.000.040.080.060.050.050.030.030.06
Debt Ratio 0.010.000.040.070.050.040.040.030.030.06
Equity Ratio 0.910.730.830.840.870.860.880.950.960.93
Valuation
Enterprise Value -447.40M-441.31M-477.52M-368.31M-340.45M-481.15M-430.71M-422.73M-834.19M-808.48M-739.16M-702.95M
Return Ratios
Return on Sales -4.87%-16.03%-61.60%-66.93%-17.12%-0.57%-7.22%-13.27%-0.91%-206.91%
Return on Capital Employed -0.55%-0.49%-0.46%-0.32%-0.24%-0.22%-0.27%
Return on Assets -0.46%-0.49%-0.45%-0.37%-0.22%-0.20%-0.28%
Return on Equity -0.25%-0.45%-0.54%-0.57%-0.52%-0.43%-0.24%-0.21%-0.29%